Santen Pharmaceutical Co., Ltd.

OTCPK:SNPH.F Stock Report

Market Cap: US$3.8b

Santen Pharmaceutical Management

Management criteria checks 2/4

Santen Pharmaceutical's CEO is Takeshi Ito, appointed in Sep 2022, has a tenure of 3.92 years. total yearly compensation is ¥252.00M, comprised of 42.9% salary and 57.1% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth $1.18M. The average tenure of the management team and the board of directors is 3.9 years and 2.2 years respectively.

Key information

Takeshi Ito

Chief executive officer

JP¥252.0m

Total compensation

CEO salary percentage42.86%
CEO tenure3.9yrs
CEO ownership0.03%
Management average tenure3.9yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Takeshi Ito's remuneration changed compared to Santen Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

JP¥39b

Mar 31 2026JP¥252mJP¥108m

JP¥37b

Dec 31 2025n/an/a

JP¥31b

Sep 30 2025n/an/a

JP¥31b

Jun 30 2025n/an/a

JP¥31b

Mar 31 2025JP¥192mJP¥105m

JP¥36b

Dec 31 2024n/an/a

JP¥27b

Sep 30 2024n/an/a

JP¥26b

Jun 30 2024n/an/a

JP¥27b

Mar 31 2024JP¥188mJP¥94m

JP¥27b

Dec 31 2023n/an/a

JP¥28b

Sep 30 2023n/an/a

JP¥26b

Jun 30 2023n/an/a

-JP¥11b

Mar 31 2023JP¥103mJP¥71m

-JP¥15b

Compensation vs Market: Takeshi's total compensation ($USD1.58M) is below average for companies of similar size in the US market ($USD6.92M).

Compensation vs Earnings: Takeshi's compensation has increased by more than 20% in the past year.

CEO

Takeshi Ito (67 yo)

3.9yrs
Tenure
JP¥252,000,000
Compensation

Mr. Takeshi Ito has been President and Chief Executive Officer at Santen Pharmaceutical Co., Ltd. since September 12, 2022 and serves as Representative Director since April 01, 2022. He served as Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Takeshi Ito
President3.9yrsJP¥252.00m0.031%
$ 1.2m
Rie Nakajima
COO & Director3.4yrsJP¥159.00m0.019%
$ 708.3k
Kazuo Koshiji
CFO & Corporate Officerno datano datano data
Daisuke Nakata
Chief Digital & Information Officer1.6yrsno datano data
Kaori Itagaki
General Manager of Investor Relations Groupno datano datano data
Mika Masunari
Corporate Officer5.8yrsno datano data
Marianthi Psacha
Corporate Officerless than a yearno datano data
Shinichi Teramachi
Corp. Officer5.6yrsno datano data
Yoko Saiki
Corporate Officer & Chief Human Resources Officer1.6yrsno datano data
Kenji Morishima
Corporate Officer & Head of China Product Development Department12.3yrsno datano data
Takahiro Morita
Global Head of Core Principle & Sustainability and Corporate Officer4.6yrsno datano data
Takeshi Matsugi
Head of R&D Strategic Operationsno datano datano data
3.9yrs
Average Tenure

Experienced Management: SNPH.F's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Takeshi Ito
President9.1yrsJP¥252.00m0.031%
$ 1.2m
Rie Nakajima
COO & Director2.2yrsJP¥159.00m0.019%
$ 708.3k
Ippei Kurihara
Head of Japan Business Operations & Business Development and Director2.2yrsno data0.0059%
$ 224.5k
Yukiko Kuroda
Independent Outside Director1.2yrsno datano data
Junichi Asatani
Outside Auditor3.2yrsno data0.00093%
$ 35.3k
Masahiko Ikaga
Independent Outside Director2.2yrsno datano data
Minoru Kikuoka
Independent Outside Director2.2yrsno datano data
Hiroshi Isaka
Standing Corporate Auditor6.2yrsno data0.00031%
$ 11.8k
Yaeko Hodaka
Outside Auditor3.2yrsno datano data
Yuichiro Munakata
Independent Outside Auditor2.2yrsno datano data
Tetsuya Uekusa
Independent Outside Directorless than a yearno datano data
2.2yrs
Average Tenure
63.5yo
Average Age

Experienced Board: SNPH.F's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/24 18:26
End of Day Share Price 2026/06/26 00:00
Earnings2026/06/30
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Santen Pharmaceutical Co., Ltd. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hidemaru YamaguchiCitigroup Inc